[go: up one dir, main page]

BRPI0409377A - combinações de paroxetina e 1-(r)-(3,5-bis-trifluormetil-fenil)-etil] metilamida do ácido 4-(s)- (4-acentil-piperazin-1-il)-2-(r)-(4-flúor-2-metil-fenil)-pi peridina-1-carboxìlico para tratamento de depressão e/ou ansiedade - Google Patents

combinações de paroxetina e 1-(r)-(3,5-bis-trifluormetil-fenil)-etil] metilamida do ácido 4-(s)- (4-acentil-piperazin-1-il)-2-(r)-(4-flúor-2-metil-fenil)-pi peridina-1-carboxìlico para tratamento de depressão e/ou ansiedade

Info

Publication number
BRPI0409377A
BRPI0409377A BRPI0409377-1A BRPI0409377A BRPI0409377A BR PI0409377 A BRPI0409377 A BR PI0409377A BR PI0409377 A BRPI0409377 A BR PI0409377A BR PI0409377 A BRPI0409377 A BR PI0409377A
Authority
BR
Brazil
Prior art keywords
combinations
paroxetine
piperazin
anxiety
methylphenyl
Prior art date
Application number
BRPI0409377-1A
Other languages
English (en)
Inventor
Sergio Melotto
Mauro Corsi
Renzo Carletti
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0409377A publication Critical patent/BRPI0409377A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMBINAçõES DE PAROXETINA E 1-(R)-(3,5-BISTRIFLUORMETIL-FENIL)-ETILI METILAMIDA DO áCIDO 4(S)- (4-ACETIL-PIPERAZIN-1-IL)-2-(R)-(4-FLúOR-2-METILFENIL)-PIPE RIDINA-1-CARBOXìLICO PARA TRATAMENTO DE DEPRESSãO E/OU ANSIEDADE". A presente invenção diz respeito a combinações terapêuticas compreendendo paroxetina ou sais ou solvatos fisiologicamente aceitáveis desta e ¢1-(R)-(3,5-bistrifluormetil-fenil)-etil!-metilamida do ácido 4-(S)-(4Acetil-piperazin-1-il)-2-(R)-(4-flúor-2~metil-fenil)-piperidina-1-c arboxílico ou sais ou solvatos farmaceuticamente aceitáveis deste, a composições farmacêuticas contendo as ditas combinações e seu uso no tratamento de depressão e/ou ansiedade.
BRPI0409377-1A 2003-04-17 2004-04-16 combinações de paroxetina e 1-(r)-(3,5-bis-trifluormetil-fenil)-etil] metilamida do ácido 4-(s)- (4-acentil-piperazin-1-il)-2-(r)-(4-flúor-2-metil-fenil)-pi peridina-1-carboxìlico para tratamento de depressão e/ou ansiedade BRPI0409377A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments
PCT/EP2004/004122 WO2004091616A1 (en) 2003-04-17 2004-04-16 Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl-phenyl -piperidine-1-carboxylic acid [1- (r) -(3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety

Publications (1)

Publication Number Publication Date
BRPI0409377A true BRPI0409377A (pt) 2006-04-25

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0409377-1A BRPI0409377A (pt) 2003-04-17 2004-04-16 combinações de paroxetina e 1-(r)-(3,5-bis-trifluormetil-fenil)-etil] metilamida do ácido 4-(s)- (4-acentil-piperazin-1-il)-2-(r)-(4-flúor-2-metil-fenil)-pi peridina-1-carboxìlico para tratamento de depressão e/ou ansiedade
BRPI0409379-8A BRPI0409379A (pt) 2003-04-17 2004-04-16 combinações de paroxetina e 1-(r)-(3-,5-bis-trifluormetil-fenil)-etil] metilamida do ácido (s)-(4-flúor-2-metil-fenil)-piperazina-1-carboxìlico para tratamento de depressão e/ou ansiedade

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0409379-8A BRPI0409379A (pt) 2003-04-17 2004-04-16 combinações de paroxetina e 1-(r)-(3-,5-bis-trifluormetil-fenil)-etil] metilamida do ácido (s)-(4-flúor-2-metil-fenil)-piperazina-1-carboxìlico para tratamento de depressão e/ou ansiedade

Country Status (18)

Country Link
US (4) US20060217395A1 (pt)
EP (4) EP1615641A1 (pt)
JP (4) JP2006523650A (pt)
KR (2) KR20060003875A (pt)
CN (2) CN1809359A (pt)
AU (2) AU2004229179A1 (pt)
BR (2) BRPI0409377A (pt)
CA (2) CA2522313A1 (pt)
CO (1) CO5700753A2 (pt)
GB (1) GB0308968D0 (pt)
IS (2) IS8128A (pt)
MA (2) MA27730A1 (pt)
MX (2) MXPA05011064A (pt)
NO (2) NO20055368L (pt)
PL (2) PL377857A1 (pt)
RU (2) RU2005135649A (pt)
WO (4) WO2004091616A1 (pt)
ZA (2) ZA200508067B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (en) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Stable dosage form of an antidepressant
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
WO2012175434A1 (en) * 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
EP0977573A1 (en) * 1997-04-24 2000-02-09 MERCK SHARP & DOHME LTD. Use of an nk-1 receptor antagonist and an ssri for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
CO5261559A1 (es) * 1999-12-17 2003-03-31 Schering Corp Antagonistas de neurokinina selectivos
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
TW200300347A (en) * 2001-11-13 2003-06-01 Schering Corp Nk1 antagonists
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
MA27730A1 (fr) 2006-01-02
IS8129A (is) 2005-11-15
EP1653956A1 (en) 2006-05-10
WO2004091615A1 (en) 2004-10-28
MA27731A1 (fr) 2006-01-02
US20060287325A1 (en) 2006-12-21
CN1809359A (zh) 2006-07-26
EP1615642A1 (en) 2006-01-18
RU2005135649A (ru) 2006-03-20
WO2004091617A1 (en) 2004-10-28
KR20060003876A (ko) 2006-01-11
AU2004229179A1 (en) 2004-10-28
US20060217395A1 (en) 2006-09-28
IS8128A (is) 2005-11-15
US20060241143A1 (en) 2006-10-26
WO2004091624A1 (en) 2004-10-28
MXPA05011063A (es) 2005-12-12
ZA200508068B (en) 2007-02-28
MXPA05011064A (es) 2006-04-18
JP2006523651A (ja) 2006-10-19
BRPI0409379A (pt) 2006-04-25
WO2004091616A1 (en) 2004-10-28
CA2522313A1 (en) 2004-10-28
NO20055368L (no) 2005-11-14
EP1615641A1 (en) 2006-01-18
CA2522311A1 (en) 2004-10-28
JP2006523652A (ja) 2006-10-19
GB0308968D0 (en) 2003-05-28
JP2006523649A (ja) 2006-10-19
ZA200508067B (en) 2007-02-28
RU2005135647A (ru) 2006-06-10
PL377858A1 (pl) 2006-02-20
EP1613325A1 (en) 2006-01-11
CO5700753A2 (es) 2006-11-30
KR20060003875A (ko) 2006-01-11
AU2004229181A1 (en) 2004-10-28
JP2006523650A (ja) 2006-10-19
NO20055367L (no) 2005-11-14
CN1809355A (zh) 2006-07-26
US20060241124A1 (en) 2006-10-26
PL377857A1 (pl) 2006-02-20

Similar Documents

Publication Publication Date Title
SG157378A1 (en) Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-næ-(4-(2- methylpropyloxy)phenylmethyl)carbamide and their preparation
BRPI0410563B8 (pt) compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
BRPI0513713A (pt) derivados de piperazina úteis para o tratamento de distúrbios gastrointestinais
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
CY1114118T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη
ES2548878T3 (es) Métodos de tratamiento de úlceras de la piel
NZ600637A (en) Pyrazole compounds as crth2 antagonists
SE0401342D0 (sv) Therapeutic compounds
BRPI0409377A (pt) combinações de paroxetina e 1-(r)-(3,5-bis-trifluormetil-fenil)-etil] metilamida do ácido 4-(s)- (4-acentil-piperazin-1-il)-2-(r)-(4-flúor-2-metil-fenil)-pi peridina-1-carboxìlico para tratamento de depressão e/ou ansiedade
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
MY145919A (en) Pharmaceutical formulation comprising neurokinin antagonist
DE602005007339D1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
WO2009032843A3 (en) Deuterated ethambutols and their use
ECSP044979A (es) Uso de bibn4096 en combinación con otros fármacos antimigrañosos para el tratamiento de migraña
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
BRPI0414448A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e um agonista/antagonista de estrogênio
Berkowitz et al. Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged⩾ 12 years with moderate to severe seasonal allergic Rhinitis: A pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies
DE60135390D1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
DOP2005000085A (es) Composicion farmaceutica antimicobacterial
AR043793A1 (es) Uso del hidrocloruro de la base del principio activo 1-[n2-[3,5-didromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptano para el tratamiento de la migrana
TW200738635A (en) New salt
NO20081079L (no) Nytt salt III
NO20081080L (no) Nytt salt I
FR2875499B1 (fr) Nouveaux derives pyridiniques d'indolin-2-one, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]